Divis Laboratories Q1 FY27 Earnings Call: Guides Double-Digit Revenue Growth, Adopts Three-Month Inventory Buffer (DIVISLAB)

Divis Laboratories Ltd held its Q1 FY27 earnings call on August 01, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Headline Financials

• Rs.3,144 crores — consolidated total income for Q1 FY 2026-2027, compared to Rs.2,529 crores in Q1 FY 2025-2026 (YoY growth of ~24%).
• Rs.902 crores — consolidated PAT for Q1 FY 2026-2027, up from Rs.535 crores in Q1 FY 2025-2026.
• 10% constant currency — standalone revenue growth in Q1 FY 2026-2027; standalone total income stood at Rs.3,037 crores (vs. Rs.2,476 crores YoY).
• ~90% of revenue — exports' contribution to standalone revenue; Europe and North America accounted for 75% of exports in Q1 FY 2026-2027.
• Rs.3,611 crores — cash and cash equivalents as of 30 June 2026; trade receivables at Rs.3,056 crores and inventories at Rs.4,413 crores.

Revenue Composition & Growth Drivers

• 60:40 split — custom synthesis contributed 60% of total revenue in Q1 FY 2026-2027, while generics contributed 40%; the CS mix supported marginally higher margins for the quarter.
• Rs.298 crores — global nutraceutical business revenue in Q1 FY 2026-2027, up from Rs.250 crores in Q1 FY 2025-2026 and Rs.240 crores in Q4 FY 2025-2026.
• 100+ offerings — nutraceutical portfolio now exceeds 100 products across human and animal health and dietary supplements; the company marked 20 years in this segment during FY 2026-2027.
• Stable generic volumes — management highlighted continued competitive pricing pressure in generics; recent price increases were attributed to raw material cost inflation (solvents doubled or tripled) due to the Middle East situation, not an end to structural pricing pressure.
• 4 DMFs filed — for generic products; customers are qualifying validation batches, with commercial volumes expected in the next 3 to 6 months (implying within FY 2026-2027 or early FY 2027-2028).

Validation Projects, Peptides & Competitive Edge

• 3 validation projects — completed in Q1 FY 2026-2027, each supporting a major capex program for a different molecule; several other validation projects are ongoing, with commercialization dependent on customer regulatory approvals and inspections.
• 18 to 20 projects — currently commercialized or being commercialized across the custom synthesis pipeline; management declined to disclose phase-wise split due to confidentiality agreements.
• 30-year track record — CEO emphasized the company's reputation as one of the first CDMOs in India, with differentiation built on sustainability, safety, EHS, and employee healthcare systems rather than pricing alone; management stated they "do not compete with customers."
• Peptide business — backward integration from basic raw materials through building blocks, protected amino acids, dipeptides, tripeptides, and fragments; capacity expansion underway with additional 3,000-litre SPPS reactors being installed at Karkapatla.
• Contrast media — iodine — multi-year contracts signed with two customers; commercialization started for one, with the second expected within the next few months (within FY 2026-2027). Gadolinium-based contrast media remains at qualification stage (phase 2/3), awaiting customer gateway approvals.
• GLP-1 programs — management declined to disclose if commercial quantities were supplied in Q1 FY 2026-2027, but confirmed validation of three large projects and several others in pipeline.

Margin Bridge, Solvent Volatility & Inventory Buffer

• ~68% gross margin — reported for Q1 FY 2026-2027; management cautioned against extrapolating this quarterly figure to the rest of the year due to lumpiness from product mix and validation timing.
• FY 2026-2027 EBITDA margin — management expects full-year EBITDA margin to be similar to FY 2025-2026 levels; Q1 benefited from a favourable CS mix but faced elevated solvent costs and a net forex loss of Rs.7 crores (vs. a gain of Rs.39 crores in Q1 FY 2025-2026).
• Rs.500 crores inventory change — in Q1 FY 2026-2027, far above the typical Rs.50–100 crores quarterly range; CFO Meena Devi attributed this to increased production, validation project builds, and price increases across raw materials, WIP, intermediates, and finished goods.
• 3-month rolling inventory buffer — adopted during Q1 FY 2026-2027, shifting from just-in-time procurement to ensure supply continuity amid Middle East-driven volatility; management confirmed the strategy will continue as long as macro uncertainty persists.
• Analyst estimate — after adjusting for Rs.300–400 crores of incremental inventory change, analysts calculated an adjusted gross margin of 55–58% and an adjusted EBITDA margin of 28–30% for Q1 FY 2026-2027, implying underlying margin pressure from solvent cost inflation.
• Solvent pricing — remained volatile during Q1 FY 2026-2027 with no clear trend of normalization; management declined to predict future inventory changes, citing dependence on uncontrollable macro-geopolitical factors.

Three Major Projects, Unit 3 & Technology Investments

• ~Rs.2,000 crores combined capex — for three major programs disclosed to the stock market; approximately 70% capitalised to date (implying ~Rs.1,400 crores spent, ~Rs.600 crores remaining), with validation activities ongoing.
• Rs.451 crores — capitalised assets during Q1 FY 2026-2027; capital work-in-progress stood at Rs.2,034 crores as of 30 June 2026.
• Unit 3 (Kakinada) — currently performing backward integration work to free up capacity at Units 1 and 2; long-term plan is to qualify the facility for all regulatory clearances and eventual commercial supply.
• Multiple 3,000-litre HPTA units — being installed at Karkapatla to capture future opportunities in custom synthesis and peptide fragments.
• Technology development — initiatives in continuous flow chemistry, biocatalysis, and advanced automation are improving process safety, reproducibility, and sustainability; capacity expansion in solid-state and liquid-state workspace interfaces continues.
• Combined utilization — across all three manufacturing units was 80–85% in Q1 FY 2026-2027; CEO Dr. Kiran S. Divi stated utilization at 85%.

Guidance, Approvals & Macro Headwinds

• Double-digit revenue growth — management reiterated this target for FY 2026-2027, while citing potential lumpiness due to regulatory validation and approval timelines across the custom synthesis portfolio.
• EBITDA margin — expected to be similar to FY 2025-2026 levels for the full year FY 2026-2027; gross margin trajectory depends on the pace of regulatory approvals and subsequent ramp-up of commercial volumes in custom synthesis.
• Dedicated innovator project — company is ready for submissions and inspections, but commercial supply timing depends on customer filing; management expects commercial supply in the latter part of FY 2026-2027.
• Regulatory approvals — faster approvals could improve the CS mix and support margin expansion; management declined to provide specific volume or revenue guidance for validation-to-commercial conversion due to product-specific variability (annual demand ranges from under 1,000 kg to 5,000–6,000 tonnes).
• Key risks — solvent cost volatility remains elevated with no clear normalization trend; geopolitical uncertainty in West Asia continues to affect supply chains and logistics costs; port congestion and container shortages persist; management has adopted a 3-month rolling inventory buffer to mitigate disruption risk.
• Inventory outlook — management explicitly declined to forecast inventory changes for the remaining quarters of FY 2026-2027, citing dependence on uncontrollable macroeconomic and geopolitical factors.